RESEARCH ARTICLE

AN ANTIVIRAL DRUG COMBINATIONAL STUDIES AGAINST HIV- A COMPUTATIONAL DRUG REPOSITIONING APPROACH

[1,]*Yunusa, A., [1]Bello, S.O., [1]Chika, A., [2]Yakubu A.

[1]Department of Pharmacology and therapeutics, Usmanu Danfodiyo University, Sokoto, Nigeria
[2]Department of Internal Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria

ARTICLE INFO

ABSTRACT

This study was aimed at identifying two promising generic drugs and conduct an antiviral drug combination studies against HIV. It has two components; computational and *in-vitro* studies. The computational study entails sequential screening of all FDA approved drugs (1491) against three protein targets; through structural- and ligand- based pharmacophore screening followed by molecular docking of the selected drugs against the viral targets. Two (2) drugs with the best binding affinities against the viral targets were chosen for an *in-vitro* confirmation of activity. The non-toxic concentrations used for the study were established from MTT cytotoxicity study using C_{max} of the drugs as a guide. Iodixanol and sirolismus had the highest binding affinities against the three protein targets. In the antiviral drug combination studies, synergism (CI<1) were demonstrated at the three graded concentrations.

INTRODUCTION

Infectious diseases are becoming more alarming with high morbidity and mortality in developing countries like Africa (Yamani et al., 2017). HIV for instance is often regarded as incurable and fatal disease (Yamani et al., 2017). Again, the emergence of drug resistant strains have compromised the efficacy of most antiretroviral agents; some have troublesome and unbearable side effects while some are less efficacious (Kühnert et al., 2018; Wang et al., 2018). The high cost of developing drugs has limited the number of antiviral agents into a short list (Bhandari, 2017). Again, available anti-retroviral agents are both costly and of limited efficacy. The burden of HIV/AIDS for instance is of great public healthy importance. Globally, 1.8 million people became infected with HIV in 2017 alone – that is three people every minute (Zazzi et al., 2018). It is also the second leading cause of death next to lower respiratory tract infections in Africa (Awofala and Ogundele, 2018). The prevalence of HIV in Nigeria has increased from 1.8% in 1991 to 3.2% in 2014 (Awofala and Ogundele, 2018). If no intervention, this value was predicted to increase exponentially in another twenty years (Awofala and Ogundele, 2018).

Nigeria was rated second HIV most prevalent country worldwide (Awofala and Ogundele, 2018). Currently available anti-retroviral agents include nucleosides reverse transcriptase inhibitors (NRTIs), non-nucleosides reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, integrase inhibitors and CCR5 receptor antagonist (Barnabas et al., 2017). Gibson et al. (2017) reported more than 50% of treatment failures as due to development of drug resistance strains. Antiretroviral toxicity and resistance rank high on the list of problems that must be overcome to gain the long-term benefits associated with highly active anti-retroviral therapy (Barnabas et al., 2017). Toxicity is inherent to all the known anti-retroviral drugs. For example; protease inhibitor has been associated with hyperlipidaemia, hyperglycemia, gastrointestinal symptoms, and body-fat distribution abnormalities. For non-nucleoside reverse transcriptase inhibitors, rashes and hepatotoxicity have been reported while nucleoside reverse transcriptase inhibitors are associated with lactic acidosis, hypersensitivity reactions, neuropathies, pancreatitis, anaemia, and neutropenia (Glynn and Bhikha, 2017). Drug repositioning approach might be a better alternative for discovering more effective and less harmful agents. Several scientist have attempted to reposition approved drugs for the treatment of HIV. For instance, Dai et al. (2017) reported the novel anti-HIV effect of seven (7) approved drugs- cetrorelix, dalbavancin, daunorubicin, doxorubicin,

---
Corresponding author: **Yunusa, A.,**
[1]Department of Pharmacology and therapeutics, Usmanu Danfodiyo University, Sokoto, Nigeria.

epirubicin, idarubicin and valrubicin. This was on the basis of computational screening of approved drugs using anti-HIV predictor software followed by *In-vitro* confirmation of activity. Again, in an attempt to re-position clinically approved antimetabolites for HIV infection, seven (7) antimetabolites were tested against HIV infected cell lines (Clouser et al., 2010).

Aim of the Study: To identify two promising generic drugs and conduct an antiviral drug combination studies against HIV.

Objectives of the Study

- To develop a local database for FDA-Approved drugs and three (3) HIV viral protein targets.
- To screen commercially approved drugs using structural-based and ligand-based pharmacophores as templates.
- To run a docking simulation of the selected drugs against the three protein targets and select best two (2).
- To run an *in-vitro*-antiviral drug combination studies of the two (2) selected drugs against HIV infected 3T3 cell line.

MATERIALS AND METHODS

Criteria for Viral Targets Selection: The HIV viral targets were selected based on validated selection criteria and scoring (Ansari et al., 2018). The criteria include: involvement in a critical pathway necessary for the survival and replication of the viruses*,* confirmed or putative targets of known Antiviral agents, absence of significant cross talk from NCBI blast search, drugability of the target (easily accessible binding site) and site or location of the protein target within virus; either on the cell surface/cytoplasm or inside the nucleus (Ansari et al., 2018; Sliwoski et al., 2014). Targets with score of at least 80 out of 115 were selected and considered as critical in the survival and multiplication of the viruses (Sliwoski et al., 2014).

Development of Local Database of Viral Protein Targets from Protein Data Bank: Protein Data Bank (PDB) is an archive of 3D structures of about 35,000-50,000 biological molecules. Three (3) HIV viral targets (in PDB text format) necessary for their survival and multiplication were selected and downloaded from the PDB website (www.rcsb.org) and saved in PDB text format. A local Database was created for the viral targets in my personal computer (Smart et al., 2018).

Development of Local Database for FDA-Approved Drug from Drug Bank: A DrugBank is a drug Database that contains more than 4,000 compounds linked to about 14,000 molecular targets. All (1491) FDA-Approveddrugs were downloaded from DrugBank website (www.drugbank.ca) and saved in structural data format (SDF) (Wishart et al., 2017).

Structure-based Pharmacophore Screening: Ligand Scout advanced molecular design software was used to generate structure-based pharmacophore for each viral targets using the target- co-crystalized ligand complex as a template (Ansari et al., 2018).

Ligand-Based Pharmacophore Screening: Ligand-based pharmacophore was generated using all the co-crystalized ligands for the nine different viral targets as templates. The generated ligand-based pharmacophore can be merged or shared similarity pharmacophore (Ansari et al., 2018).

Screening of FDA-Approved Drugs using the Structural and Ligand-Based Pharmacophores as Templates: The structure and ligand-based pharmacophores were copied to the screening perspective using the copy board widget. Approved drugs downloaded from the DrugBank were loaded to the screening Database using the "create and load screening database". The generated pharmacophores were screened against the approved drugs and the drugs with similar pharmacophores were displayed in the tabular form compatible with excel (Ellingson and Baudry, 2014).

Docking Simulation of the Selected Drugs from Pharmacophore Screening against three (3)Viral Targets using PyRx Virtual Screening Tool Importation of macromolecules from the local Database: To import macromolecule from local Database, File > Import molecule was selected, this displays "import molecule wizard" carrying different options. Workspace Tarball> local File was then selected and "Next" button clicked followed by Finish button. Shortly an "Import Completed Successfully" dialog appears, then OK button was clicked. The 3D structure of themacromolecule was displayed in the workspace and the protein ID appears in the "molecule tab" of the navigator panel. Atoms of the macromolecule were viewed in the workspace by deselecting and selecting them in the "molecule tab" of the navigator panel. The macromolecule was inspected in the workspace by right clicking and holding the mouse. The binding site of the co-crystallized area examined, in shape, size, polarity and accessibility (Ellingson and Baudry, 2014).

Importation of ligands from the local database: To import ligands from the local Database, select open babel button in the control panel of the PyRx tool. Clicking the insert new item tab on the upper left hand corner of the open babel panel, a "choose open babel supported file" box appears that takes you to the ligand Database in my personal computer. The ligand of interest was then selected and imported into the PyRx. The selected ligands appear in the open babel results table displaying the drugs ID, formula, weight and LogP. Minimized atomic coordinates of the ligand was created using "the minimize all" widget. The minimized coordinate of the ligands right clicked and different options displayed. The option "Covert all to autodock ligand PDBQT" was selected. The PDPQT format of the ligand appears in the ligand compartment of the autodock navigator area (Ellingson and Baudry, 2014).

Running the molecular docking simulation: The ligands of interest were selected from the autodock widget and "select ligand" button pressed, followed by the forward button. This automatically input the ligands into the ligand list in the control panel of PyRx software. Again, the macromolecules were selected from the autodock widget and "select macromolecule" button pressed followed by the forward button and this automatically input macromolecules into the macromolecule list in the control panel (Ellingson and Baudry, 2014). To run vina, the "run vina" was clicked, then forward button pressed. Finally "analyze result" was selected then forward button. This displays the binding affinities of the various poses against the ligands. The lower the binding affinities the better the protein-ligand interaction, since

molecules interact to conserve energy (Dallakyan and Olson, 2015). The Analyze results page is where the final docking results were presented. The table was sorted according to the values of the binding energies. The table row was selected one by one to see the corresponding docking pose for each ligand-protein complex in the 3D scene. The numerical results were exported as a Comma-Separated Values (CSV) file compatible with excel (Dallakyan and Olson, 2015).

Selection of the Best two (2) Performing Drugs for In-vitro Antiviral Studies: Two (2) drugs with overall best binding affinities against the nine viral targets were selected for confirmation of activity in the wet laboratory using *in-vitro* cell line based assay.The analytical grade of the selected drugs were purchased from sigma Aldrich.

In-vitro Model for HIV: Ten thousand cells/well were cultured in a 24-well plates for 24 hours to achieve 80-90% confluency. Media changed and the cells washed with phosphate buffer solution before addition of viral particles.

For 3T3 cell lines, 1ml of serum infected with HIV (containing 3.6 Log IU/ml of virus) was added to each well. The infected cells were maintained and propagated in DMEM (Dulbecco's Modified Eagle Medium) medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin and incubated at 37°C in a humidified and 5% CO_2 chamber (Farag and Mansour, 2016).

In-vitro Antiviral drug combination studies of the Two Selected Drugs: Twenty four hour post infection, the HIV infected cell lines were treated with three graded concentrations of the two selected drugs-in combination, DMSO treated and zidovudine (in duplicates). The viral RNA were released following lyses of theinfected cell lines at 48 hours post treatment. The viral loads for each of the treatment groups were quantified using real time PCR.

Determination of percentage viral inhibition (%VI): The percentage viral inhibition for each of tested group was calculated using the formula (Kati et al., 2015):

$$\% \, VI = \frac{VC - VTG}{VC} \times 100$$

Where VC is the viral load of the DMSO treated group
VTG is the viral load of the treated group.

Determination of IC_{50}: Nonlinear regression analysis curve generated by graph pad prism was used to extrapolate the IC_{50} of each drug against each virus. The IC_{50} is the concentration that produces 50% viral inhibition (Lo et al., 2016).

Determination of CC_{50}: Nonlinear regression analysis curve generated by graph pad prism was used to extrapolate the CC_{50} of each drug against each cell line. The CC_{50} is the concentration that produces 50% cell line viability (Lo et al., 2016).

Determination of Selectivity Index (SI): The selectivity index for each drug against a particular cell line was calculated using the formular(Lo et al., 2016).

$$SI = CC_{50}/IC_{50}$$

Determination of the Combination Index (Cl) and Dose Reduction Index (DRI): Compusyn combination software was used to generate the combination index and Dose reduction index. The CI<1 is synergism, CI>1 is antagonism while CI=1 is additivism. The DRI>1 is favorable, DRI<1 is unfavorable and DRI=1 is No dose reduction (Ashton, 2015).

Data Analysis: Data were presented in tables and graphs and were expressed as mean ±SEM. The half- maximal inhibitory concentration (IC_{50}) and half-maximal toxic concentrations (CC50) were extrapolated from a sigmoidal dose-response curve. Statistical differences between the viral loads for the different drug groups and distinct post treatment time points were analyze using a two-way ANOVA followed by Dunnet's multiple comparison tests. The *p* values of < 0.05 wereconsidered to be statistically significant. All analyses were performed using Graph Pad Prism version 7.

RESULTS

Three (3) Selected Protein Targets and their Scores: Three viral protein targets were identified and validated. The total score for each viral target was greater than 80, hence validated (Table 1).

Selected Drugs from Structure and ligand-based Pharmacophores: Three hundred and eight (308) and fourty three (43) FDA drugs were selected from the structure-based pharmacophore and ligand-based pharmacophore screening respectively.

Pharmacophores for the three (3) Viral Targets and the Two Selected Drugs: Hydrogen bond donor (HBD), Hydrogen bond acceptor (HBA), Negative ionisable areas (NI) and hydrophobic interactions (H) were the common structure and ligand-based pharmacophore features, as shown in Figures 1 to 6.

Best Two (2) Drugs and there Binding Affinities: Iodixanol and sirolismus had the best binding affinities against the three HIV targets. The binding affinities for each drug against the viral targets were greater than that for the respective co-crystalized ligands (Table 3).

Three Graded nontoxic concentrations of Iodixanol-Sirolismus for the In Vitro Antiviral Drug Combination Studies: The three graded non- toxic concentrations for iodixanol-sirolismus combination selected from MTT study were used for the Antiviral study. The concentrations of the stock solution for each drug and the volume of stock to make the highest concentrations were calculated. This is to allow easy serial dilution during drug treatment (Table 5).

DISCUSSION

The study showed that iodixanol-sirolismus combination demonstrated a concentration dependent HIV killing effect. The virucidal effect (49.9%) produced against HIV at the highest non-toxic concentration of the drug combination (4000/0.4µg/ml) was statistically not different from the effect (50%) produced by zidovudine. Remarkably, synergism (CI<1) were demonstrated at the three graded concentrations. Again, the median effective concentration of the combination was 3,351.84 µg/ml, less than iodixanol alone (6,917.68 µg/ml), indicating the high potency of the drug combination.

| S/N	Viral protein targets	Critical in the pathway (50)	Putative Antiviral drug target (30)	No signi-ficant crosstalk (15)	Drug ability of the target (10)	Location of target in virus (10)	Total Score (115)
1	HIV Reverse transcriptase (1rev)	50	30	15	10	Nucleus(5)	110
2	HIV protease (1XL2)	50	30	15	10	Nucleus(5)	110
3	HIV GP41 (3L36)	50	30	15	10	Surface(10)	115

**Figure 1. Iodixanol- HIV Reverse Transcriptase Complex**

Figure 2. Iodixanol- HIV Protease Complex


Figure 3. Iodixanol- HIV GP41 Complex

**Figure 4. Sirolismus-HIV Reverse Transcriptase Complex**


Figure 5. Sirolismus-HIV Protease Complex

Figure 6. Sirolismus-HIV GP41 Complex

Table 3. List of Best two (2) Drugs and there Binding Affinities

Ligand	HIV-RT	HIV Protease	HIV GP41
Co-crystalized ligand	-5.5	-12.3	-7.6
Iodixanol	-19.5	-20.8	-12.8
Sirolismus	-7.7	-22.8	-13.5

Keys: HIV-RT- Human immunodeficiency virus Reverse transcriptase, HIV Protease- Human immunodeficiency Protease, HIV GP41- Human immunodeficiency virus

Table 4. Percentage Viability of combined Iodixanol-Sirolimus against 3T3 Cell Lines Using MTT Cytotoxicity Assay

IODIXANOL- SIROLISMUS CONC.	HIV
1000/0.1μg/ml	70.19±0.01
2000/0.2μg/ml	66.25±3.13
4000/0.4μg/ml	65.08±0.51
8000/0.8μg/ml	51.09±0.06
16000/1.6μg/ml	48.74±0.05

Keys: HIV- Human Immunodeficiency Virus 3T3 cells- Mouse embryonic fibroblast cells MTT- 3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide CONC. Concentration.

Table 5. Three Graded nontoxic concentrations of Iodixanol-Sirolismus for the *In vitro* Antiviral Drug Combination Studies

Drugs	Lowest conc. (μg/ml)	Mid conc. (μg/ml)	Highest conc. (μg/ml)
Iodixanol-Sirolismus	1000/0.1	2000/0.2	4000/0.4

Table 6. Virucidal Effects of Iodixanol-sirolismus combination against HIV at Three Graded Concentrations

	Drugs	Smallest Conc. Viral load	%VI	Median Conc. Viral load	%VI	Highest Conc. Viral load	%VI
HIV	Iodixanol-sirolismus	$1.971 \pm 0.007^{*}$	44.8	$1.798 \pm 0.001^{*}$	49.6	$1.79 \pm 0.009^{*}$	49.9
	Zidovudine	$1.905 \pm 0.020^{*}$	46.6	$1.816 \pm 0.006^{*}$	49.1	$1.786 \pm 0.001^{*}$	50.0
	DMSO	3.57 ± 0.032		3.57 ± 0.032		3.57 ± 0.032	

Values are expressed as mean ± SEM, n=2.
Two-way ANOVA followed by Dunnet's multiple comparison tests was used.
Values of the group with superscript * are statistically significant ($p<0.05$) compared to negative control group.
Values of the group with superscript ** are statistically significant ($p<0.05$) compared to positive control group.
Values with superscript *** are statistical significant ($p<0.05$) compared to both negative and positive control groups.
The higher %VI the more the antiviral activity of the drug.
Keys: HIV- Human Immunodeficiency Virus, DMSO = Dimethyl sulfoxide (Negative control)**,** %VI = VC-VTG/VC X 100
%VI = Percentage viral inhibition, VC = viral load of the DMSO treated group
VTG = Viral load of the drug treated group, Conc.Concentration

Table 7. Selectivity index (SI) for Iodixanol and Sirolismus Combination in HIV Infected 3T3 cell line

IODIXANOL- SIROLISMUS	HBV
CC_{50}	11020
IC_{50}	7731
SI	1.40

Key: HIV- Human Immunodeficiency Virus CC_{50} is the concentration that produces 50% cell line viability IC_{50} is the concentration that produces 50% viral inhibition SI = CC_{50}/IC_{50} SI= Selectivity Index Both IC_{50} and CC_{50} were extrapolated using nonlinear regression analysis generated by graph-pad prism.

Table 8. Concentration effect (%VI) Relationship of Iodixanol, Sirolismus and the Drug Combination against HIV infected 3T3 Cell Line

Drug(μg/ml) Iodixanol	Sirolismus	Parameter Fractional inhibition (fa)	M	Dm(μg/ml)	R	CI
D1						
1000		0.433				
2000		0.486				
4000		0.473	0.11651	6917.68	0.72509	
	D2					
	0.1	0.394				
	0.2	0.287				
	0.4	0.432	0.11313	23.2606	0.23655	
D1+D2 (10000:1)						
1000+0.1		0.448				0.89454
2000+0.2		0.496				0.34158
4000+0.4		0.499	0.1477	3351.84	0.89095	0.61624

CI values of <1, =1and >1 indicate synergism, additive and antagonism respectively.
Keys: CI- Combination index M- The slope of the median effect dose; M=1, >1 and < 1 indicates hyperbolic, sigmoidal and flat sigmoidal respectively.
D1- Doses of Iodixanol D2- Doses of Sirolismus

Fa- Fractional inhibition is the virucidal effect in fraction of less than or equal to 1 Dm- The median effect dose or the IC_{50}. It signifies the potency of the drug R-The linear correlation coefficient of the mean effect plot. It signifies the conformity of the data with the mass action law. Usually r>0.9 are considered good. HIV- Human Immunodeficiency Virus 3T3- Mouse embryonic fibroblast cells.

Table 9. Combination index (CI) and Dose reduction index (DRI) of Iodixanol-Sirolismus combination at 50%, 75%, 90% and 95% Viral Inhibition against HIV

Virus	Drug combination	CR	CI values at inhibition of				DRI values at inhibition of			
			50%	75%	90%	95%	50%	75%	90%	95%
HIV	Iodixanol + Sirolismus	10000:1	0.49889	0.06763	0.00918	0.00236	2.06405	15.118	110.731	428.984
							69.4033	673.657	6538.79	30678.9

CI values of <1, =1 and >1 indicate synergism, additive and antagonism respectively. .DRI values of <1, =1 and >1 Not favourable DR, No DR and Favourable DR respectively: **Keys:** HIV- Human Immunodeficiency virus CI- Combination Index DRI- Dose reduction index CR- Combination ratio

Additionally, the dose reduction index (DRI) for the drug combination were favourable (i.e DRI greater than 1) in the treatment for HIV, further buttressing the established synergistic effect of the drug combination. Contrarily, the selectivity index for the drug combination against HIV infected cell line was 2.8, less than 4.4 and 5.8 for zidovudine and iodixanol respectively. Similar study revealed that sirolismus; a rapamycin, downregulates CCR5 density on lymphocytes (Heredia et al., 2003). In another study, sirolismus greatly enhances Vicriviroc activity against HIV-1 (Donia et al., 2010). Sirolismus/Vicriviroc combinations demonstrated a considerable synergistic activity that translated into Vicriviroc dose reductions of up to 65-fold(Donia et al., 2010). Theoretically, it may not seem appropriate to use immunosuppressive drugs in HIV-1 infected individuals. A possible explanation is that hyperactivation of the immune system may favour HIV-1 infection and that HIV infection of human T cells is favoured by T cell activation(Corbeau and Reynes, 2011). The fact that immune activation in HIV patient upregulates CCR5 expression further buttresses our argument (Kottilil et al., 2004). From the literature search using different search parameters, no known study have reported anti-HIV effect of iodixanol. However, copper iodide, an iodine-containing compound exert Antiviral activity against H1NI influenza by generating hydroxyl radicals(Vincent et al., 2016). Similarly, Povidone iodinesolution showed good efficacy against both enveloped and non- enveloped viruses including adenovirus and polyomaviruses(Eggers et al., 2015). Conflictingly, an antimicrobial study revealed iodixanol not to impede bacteria growth in a culture media(Klimentová and Stulík, 2015).

Conclusion

The result of the study showed that iodixanol-sirolismus combination produced a concentration dependent viral killing with synergism demonstrated at the three graded concentrations.

Recommendations

Further evaluation of the iodixanol and sirolismus against the three viruses using different cell lines followed by in vivo studies at biosafety level IV is recommended.

Acknowledgement

REFERENCES

Ansari, S., Kamali, A. N., Bagherzadeh, K., Amanlou, M. and Aghabalazadeh, S. 2018. Selection of Efficient Inhibitors for Caspas-9 according to Structure-Based Pharmacophore Screening Strategy and Molecular Dynamics Simulations. *Trends in Peptide and Protein Sciences,* 2**,** 35-43.

Ashton, J. C. 2015. Drug Combination Studies and Their Synergy Quantification Using the Chou–Talalay Method. *Cancer research,* 75**,** 2400-2400.

Awofala, A. A. and Ogundele, O. E. 2018. HIV epidemiology in Nigeria. *Saudi journal of biological sciences,* 25**,** 697-703.

Barnabas, G., Sibhatu, M. K. and Berhane, Y. 2017. Antiretroviral therapy program in Ethiopia benefits from virology treatment monitoring. *Ethiopian journal of health sciences,* 27**,** 1-2.

Bhandari, U. 2017. A Textbook of Pharmacology. *International Journal of Pharmaceutical and Phytopharmacological Research,* 1**,** 140.

Clouser, C. L., Patterson, S. E. and Mansky, L. M. 2010. Exploiting drug repositioning for discovery of a novel HIV combination therapy. *Journal of virology,* 84**,** 9301-9309.

Corbeau, P. and Reynes, J. 2011. Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. *Blood***,** blood-2010-12-322453.

Dai, S.-X., Chen, H., Li, W.-X., Guo, Y.-C., Liu, J.-Q., Zheng, J.-J., Wang, Q., Li, H.-J., Chen, B.-W. and Gao, Y.-D. 2017. Efficient repositioning of approved drugs as anti-HIV agents using Anti-HIV-Predictor. *bioRxiv***,** 087445.

Dallakyan, S. and Olson, A. J. 2015. Small-molecule library screening by docking with PyRx. *Chemical Biology.* Springer.

Donia, M., Mccubrey, J. A., Bendtzen, K. and Nicoletti, F. 2010. Potential use of rapamycin in HIV infection. *British journal of clinical pharmacology,* 70**,** 784-793.

Eggers, M., Eickmann, M., Kowalski, K., Zorn, J. and Reimer, K. 2015. Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses. *BMC infectious diseases,* 15**,** 375.

Ellingson, S. R. and Baudry, J. 2014. High-throughput virtual molecular docking with AutoDockCloud. *Concurrency and Computation: Practice and Experience,* 26**,** 907-916.

Farag, M. M. and Mansour, M. T. 2016. Characterization of Subviral Particles of Hepatitis B Virus Produced by HepG2. 2.15 Cell Line-In vitro Study. *International Journal of Virology and Molecular Biology,* 5**,** 1-7.

Gibson, R. M., Nickel, G., Crawford, M., Kyeyune, F., Venner, C., Nankya, I., Nabulime, E., Ndashimye, E., Poon, A. F. and Salata, R. A. 2017. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low-to middle-income countries. *Infectious diseases of poverty,* 6**,** 163.

Glynn, J. and Bhikha, R. 2017. THE PHARMACOLOGY OF WESTERN DRUGS.

Heredia, A., Amoroso, A., Davis, C., Le, N., Reardon, E., Dominique, J., Klingebiel, E., Gallo, R. and Redfield, R.

2003. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines: an approach to suppress R5 strains of HIV-1. *Proceedings of the National Academy of Sciences,* 100**,** 10411-10416.

Kati, W., Koev, G., Irvin, M., Beyer, J., Liu, Y., Krishnan, P., Reisch, T., Mondal, R., Wagner, R. and Molla, A. 2015. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. *Antimicrobial agents and chemotherapy,* 59**,** 1505-1511.

Klimentová, J. and Stulík, J. 2015. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria. *Microbiological research,* 170**,** 1-9.

Kottilil, S., Shin, K., Planta, M., Mclaughlin, M., Hallahan, C., Ghany, M., Chun, T.-W., Sneller, M. and Fauci, E. A. 2004. Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. *Journal of Infectious Diseases,* 189**,** 1193-1198.

Kühnert, D., Kouyos, R., Shirreff, G., Pečerska, J., Scherrer, A. U., Böni, J., Yerly, S., Klimkait, T., Aubert, V. and Günthard, H. F. 2018. Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. *PLoS pathogens,* 14**,** e1006895.

Lo, M. K., Shi, P.-Y., Chen, Y.-L., Flint, M. and Spiropoulou, C. F. 2016. In vitro antiviral activity of adenosine analog NITD008 against tick-borne flaviviruses. *Antiviral research,* 130**,** 46-49.

Sliwoski, G., Kothiwale, S., Meiler, J. and Lowe, E. W. 2014. Computational methods in drug discovery. *Pharmacological reviews,* 66**,** 334-395.

Smart, O. S., Horský, V., Gore, S., Svobodová Vařeková, R., Bendová, V., Kleywegt, G. J. and Velankar, S. 2018. Worldwide Protein Data Bank validation information: usage and trends. *Acta Crystallographica Section D,* 74**,** 237-244.

Vincent, M., Hartemann, P. and Engels-Deutsch, M. 2016. Antimicrobial applications of copper. *International journal of hygiene and environmental health,* 219**,** 585-591.

Wang, P., Liu, Y., Zhang, G., Wang, S., Guo, J., Cao, J., Jia, X., Zhang, L., Xiao, G. and Wang, W. 2018. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drugs Library. *Journal of virology*, JVI. 00954-18.

Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C. and Sayeeda, Z. 2017. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic acids research,* 46**,** D1074-D1082.

Yamani, L. N., Yano, Y., Utsumi, T., Wasityastuti, W., Rinonce, H. T., Widasari, D. I., Lusida, M. I. and Hayashi, Y. 2017. Profile of Mutations in the Reverse Transcriptase and Overlapping Surface Genes of Hepatitis B Virus (HBV) in Treatment-Naïve Indonesian HBV Carriers. *Japanese journal of infectious diseases,* 70**,** 647-655.

Zazzi, M., Hu, H. and Prosperi, M. 2018. The global burden of HIV-1 drug resistance in the past 20 years. *PeerJ,* 6**,** e4848.

****